Veliparib (ABT-888)

For research use only.

Catalog No.S1004 Synonyms: NSC 737664

134 publications

Veliparib (ABT-888) Chemical Structure

Molecular Weight(MW): 244.29

Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Veliparib increases autophagy and apoptosis. Phase 3.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 156 In stock
USD 120 In stock
USD 227 In stock
USD 370 In stock
USD 617 In stock
USD 990 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Veliparib (ABT-888) has been cited by 134 publications

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Veliparib increases autophagy and apoptosis. Phase 3.
Features Increases the efficacy of common cancer therapies such as radiation and alkylating agents.
Targets
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
2.9 nM(Ki) 5.2 nM(Ki)
In vitro

ABT-888 is inactive to SIRT2 (>5 μM). [1] ABT-888 inhibits the PARP activity with EC50 of 2 nM in C41 cells. [2] ABT-888 could decrease the PAR levels in both irradiated and nonirradiated H460 cells. ABT-888 also reduces clonogenic survival and inhibits DNA repair by PARP-1 inhibition in H460 cells. ABT-888 increases apoptosis and autophagy in H460 cells when combination with radiation. [3] ABT-888 also inhibits PARP activity in H1299, DU145 and 22RV1 cells and the inhibition is independent of p53 function. ABT-888 (10 μM) suppresses the surviving fraction (SF) by 43% in the clonogenic H1299 cells. ABT-888 shows effective radiosensitivity in oxic H1299 cells. Furthermore, ABT-888 could attenuate the SF of hypoxic-irradiated cells including H1299, DU145 and 22RV1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
C41 NFvDTpZMcW6jc3WgRZN{[Xl? NVT3UXRmOzBibXnu M2CyU2lvcGmkaYTpc44hd2ZiUFHSVFEhf2m2aDDFR|UxKG:oIECuNFAzKM7:TR?= NEX0UoQyQTh6OEe2NC=>
Jurkat M4DnRWtqdmG|ZTDBd5NigQ>? NWOzeIJzQTZiaB?= NIXCT|JFVVOR M4jBdmlvcGmkaYTpc44hd2ZiUFHSVFEh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIH;mJINmdGxidnnhZoltcXS7IIfpeIghTUN3MDDv[kA{KM7:TR?= M3qzb|I{QDVyMUm5
Capan1 NYnU[VdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGX2TlU4OiCq M{jNNmROW09? NHrQWGpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGJTS0F{IHflcoUhdXW2YYTl[EBpfW2jbjDDZZBidjFiY3XscJMhf2m2aDDJR|UxKG:oIEO5Mlch|ryP NX3RXG81OjR|OUizPFM>
DT40 NHPjfnFEgXSxdH;4bYMhSXO|YYm= MWm3NkBp NFTYN5JFVVOR NHG2T4tEgXSxdH;4bYNqfHliYXfhbY5{fCClaHnjb4VvKEKUQ1GyMYRm\mmlaXXueEBFXDRyIHPlcIx{ NXPtNFN6OjR7MkK1PFc>
ML-1 M4TiTmFxd3C2b4TpZ{BCe3OjeR?= M4nh[|IvPSEQvF2= NHHwR3gzPCCq NWX1blhrTE2VTx?= MofqV5lv\XKpaYP0bYNidGy7IHXubIFv[2W|IGTSRWlNNWmwZIXj[YQh[XCxcITvd4l{KGmwIF3MMVEh[2WubIO= NWjaRnRFOjR6OUWxN|U>
HCT-116 M2rWfGtqdmG|ZTDBd5NigQ>? NWftcnVMOC53IN88US=> NXvxb3JQOjRiaB?= M{HwUHBCWlBiYXP0bZZqfHliZHXjdoVie2W| MV[yN|A2PDJzMx?=
UM-SCC1 NHrsTZhEgXSxdH;4bYMhSXO|YYm= MXOxNEDPxE1? M3G5XFI1KGh? NVvtdnhSWmWmdXPld{B1cGViY3XscEB3cWGkaXzpeJk> NXLjOZJ1OjF7MUK2NlA>
FaDu MXnDfZRwfG:6aXOgRZN{[Xl? Mn;FNVAh|ryP NYm4NHk4OjRiaB?= NGntU4tT\WS3Y3XzJJRp\SClZXzsJJZq[WKrbHn0fS=> M3jNTVIyQTF{NkKw
PC-3 M{P0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3GNVAh|ryP M{fOO2lv\HWlZYOgZUB{cWewaX\pZ4FvfCCrbnjpZol1cW:wIHnuJINwdG:weTDmc5Ju[XSrb39CpC=> NETrT5IzOTV5MUmxNi=>
EoL-1-cell MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGe2WpZKSzVyPUGuNFc6QCEQvF2= NFTvPZBUSU6JRWK=
NCI-SNU-5 NX\3WW1OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnH[IZiUUN3ME2zMlEzQDRzIN88US=> NX\pR5ZwW0GQR1XS
BV-173 NHLXfmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1qyRmlEPTB;NT60OVQxQSEQvF2= MkHSV2FPT0WU
HCC1806 NF\IbolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIn1foFKSzVyPUWuO|UyPzNizszN NXKwN3c{W0GQR1XS
COLO-680 Mm\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXW2Vo84UUN3ME22MlIyPDB4IN88US=> NITBSm1USU6JRWK=
HCC2218 NIT4SFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTCVldKSzVyPUeuO|k4ODRizszN NGi3eJZUSU6JRWK=
SK-MEL-24 NYq2d|ZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\uRXdKSzVyPUeuPFE6OjRizszN MnPZV2FPT0WU
NCI-H720 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrNTlBKSzVyPUiuOFM3ODNizszN NFrET29USU6JRWK=
KASUMI-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFft[lhKSzVyPUiuPFkzPjZizszN M2KwXXNCVkeHUh?=
HAL-01 NVX4boZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXQTWM2OD17Lki4OlIh|ryP MmnOV2FPT0WU
CAL-33 NGfnT2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlq0TWM2OD1zMD60N|Qh|ryP NV3mRXdzW0GQR1XS
SK-MEL-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7ocpJKSzVyPUGyMlQ3PjNizszN M3f6dXNCVkeHUh?=
Ramos-2G6-4C10 MoDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF31U|NKSzVyPUGyMlQ4PTJizszN MWLTRW5ITVJ?
KY821 MnXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPLbItKSzVyPUGyMlQ5PSEQvF2= M2izVnNCVkeHUh?=
HEC-1 Mn\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTF{LkmxPVYh|ryP NHfib3pUSU6JRWK=
SK-NEP-1 M2jMbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnPeppKSzVyPUGzMlE3PiEQvF2= M3;ZZnNCVkeHUh?=
MN-60 NXPNbGJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUCzVHRZUUN3ME2xN{42Ozh7IN88US=> NWO2bIpyW0GQR1XS
DU-145 NYDHRlFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjHc2QzUUN3ME2xN{46ODV|IN88US=> Mof1V2FPT0WU
EW-3 NYm2T|Q{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPDcJB3UUN3ME2xOE42PTZ3IN88US=> NHz5bYJUSU6JRWK=
OS-RC-2 NWXWdGVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIOxNI5KSzVyPUG1Mlk2QDlizszN MUfTRW5ITVJ?
RPMI-8226 M2nOcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTF4LkKwOFIh|ryP NYm2b|doW0GQR1XS
ChaGo-K-1 Ml3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTF4LkWzNlUh|ryP M1S0N3NCVkeHUh?=
DEL MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfnenhbUUN3ME2xOk43PzF5IN88US=> NGCyeVNUSU6JRWK=
GP5d NXXWfYJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTF5LkC1N{DPxE1? NH\nU2xUSU6JRWK=
COLO-668 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3CTWM2OD1zNz62Nlk1KM7:TR?= M{DGT3NCVkeHUh?=
H9 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{L0XmlEPTB;MUiuNlg{OyEQvF2= MV\TRW5ITVJ?
NKM-1 MnnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDzZW9KSzVyPUG4MlUyOTlizszN M2XMcXNCVkeHUh?=
KYSE-150 M4nKRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrLcHVKSzVyPUG4Mlk6QDZizszN MVXTRW5ITVJ?
Daoy NWLoTIc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nzSmlEPTB;MUmuOVY1QSEQvF2= M1W4N3NCVkeHUh?=
ECC10 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnJb4VKSzVyPUKwMlc1PTVizszN M2G3RnNCVkeHUh?=
A388 NFH3TlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjDTWM2OD1{MT65NFkyKM7:TR?= MYDTRW5ITVJ?
MHH-NB-11 MmfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml2xTWM2OD1{Mz6xN|Y{KM7:TR?= Mnf0V2FPT0WU
HCC1937 MnPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHFTWM2OD1{ND63OFYh|ryP MX7TRW5ITVJ?
TGBC11TKB MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DTcWlEPTB;MkWuOlg3OyEQvF2= MVzTRW5ITVJ?
CTV-1 M17EXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfUTWM2OD1{NT64PVY6KM7:TR?= NFPWUnpUSU6JRWK=
NCI-H2029 NIfXbIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXWxRXkzUUN3ME2yOk41OjN6IN88US=> M2rz[3NCVkeHUh?=
HLE MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfke5NKSzVyPUK3MlA2PCEQvF2= NVHse2FPW0GQR1XS
NCI-H1693 MoXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPGNIZOUUN3ME2yO{4zQDl6IN88US=> NIKye|ZUSU6JRWK=
HCC70 NH3nOFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFL3dGJKSzVyPUK3MlczPDZizszN NFSwSW5USU6JRWK=
BEN MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTJ5Lkm1OlYh|ryP NF6yNFhUSU6JRWK=
LB771 MkTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTJ6LkizO|Mh|ryP MlzOV2FPT0WU
697 NUfYVVIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTJ7LkCyN|Uh|ryP MnjHV2FPT0WU
LU-139 M1j0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjTTWM2OD1{OT6zO|Q5KM7:TR?= NFLpTnhUSU6JRWK=
EW-13 M1Pjemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTJ7LkO4NVQh|ryP NVnlZ4gzW0GQR1XS
MOLT-13 NETJTXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rWZ2lEPTB;MkmuN|gyPCEQvF2= M1fMVHNCVkeHUh?=
L-363 M3XhXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XhcmlEPTB;MkmuOFc6QCEQvF2= NFv3S4FUSU6JRWK=
EM-2 NILMRYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITr[ZhKSzVyPUK5MlQ6ODFizszN NF\YdW9USU6JRWK=
RS4-11 NXL4R3V2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{H3OWlEPTB;M{CuOFI1OSEQvF2= MljuV2FPT0WU
A2780 NF7tXolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7F[mRKSzVyPUOwMlc1PTdizszN NFntNnFUSU6JRWK=
KU812 M33oTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjHZYJKSzVyPUOyMlM3PDJizszN NEe1UoxUSU6JRWK=
COLO-684 M{Ozd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTN|LkO1PVkh|ryP NULkclNVW0GQR1XS
MFE-280 M17Ddmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIL1dHVKSzVyPUOzMlM5QDlizszN MVfTRW5ITVJ?
KG-1 NHLRbnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTN|Lk[wNFEh|ryP M3XMUnNCVkeHUh?=
JVM-3 M4Wwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHroNmNKSzVyPUO1MlU5PjhizszN M3jkfHNCVkeHUh?=
MV-4-11 M4fVOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVv6Tm5SUUN3ME2zOU45PDl7IN88US=> NXO1Olk6W0GQR1XS
LAMA-84 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljCTWM2OD1|Nj63N|Q2KM7:TR?= MkS4V2FPT0WU
MOLT-16 MnnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLNVmJKSzVyPUO2Mlk2OiEQvF2= NHHyUZRUSU6JRWK=
H4 NFHM[IJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYn4OVNCUUN3ME2zO{42PjdizszN MojLV2FPT0WU
T47D Mn\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYG0U4JTUUN3ME2zO{44ODF6IN88US=> NXrRclFkW0GQR1XS
CAL-54 MlexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHsOXlKSzVyPUO3Mlk3PiEQvF2= NEfPRm5USU6JRWK=
SW982 M2TUeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3UZVVKSzVyPUO4MlA6QThizszN MVLTRW5ITVJ?
IGROV-1 NXHz[G1CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILQe|NKSzVyPUO5MlM{ODRizszN NF\DeGtUSU6JRWK=
NB14 NVjP[FRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfTOHR6UUN3ME20NE44ODNzIN88US=> M2XPVXNCVkeHUh?=
HCC1187 M1nJTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk[zTWM2OD12MT6yO|cyKM7:TR?= M1HQfXNCVkeHUh?=
SBC-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnEV5NKSzVyPUSxMlMxPjNizszN NVK0VWZTW0GQR1XS
KARPAS-45 NWnDWYN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIj3UlhKSzVyPUSxMlQ5OThizszN MYDTRW5ITVJ?
MOLT-4 Mn;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XuOmlEPTB;NEKuNlU{QCEQvF2= NGHLemhUSU6JRWK=
JVM-2 NXi2NJRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTR{LkmyNFch|ryP NIH0[nBUSU6JRWK=
A4-Fuk NHfz[pFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnEVYdoUUN3ME20N{42PjlzIN88US=> Mlm4V2FPT0WU
MDA-MB-361 NVHrTIZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLWTWM2OD12Mz64OFE1KM7:TR?= NUnMV5A2W0GQR1XS
BALL-1 Mo\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3P2SWlEPTB;NEOuPVU{OiEQvF2= M1u5VHNCVkeHUh?=
T98G MortS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTR2Lki1NVch|ryP MkPoV2FPT0WU
Mo-T NInTWmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHoUXZKSzVyPUS1MlY{QDlizszN M1fmcnNCVkeHUh?=
MHH-PREB-1 M1u5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTR3Lke1PFUh|ryP MUnTRW5ITVJ?
ALL-PO NYLVR2RRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTR5LkO3PVEh|ryP NGfZb2RUSU6JRWK=
NCI-H510A MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7L[JNKSzVyPUS3MlkxOzRizszN M4fxfXNCVkeHUh?=
ML-2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;Mc2hlUUN3ME20PU44QDV4IN88US=> M2PW[3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-STAT3 / STAT3 / p-AKT(S473) / p-AKT(T308) / p-ERK / p-p38; 

PubMed: 22678161     


Effects of AG-014699, AZD-2281, ABT-888, or BSI-201 on the phosphorylation status of Stat3, Akt, ERK, and p38 in MDA-MB-468, MDA-MB-231, and Cal-51 cells after 72 h of treatment

22678161
Immunofluorescence
HuR; 

PubMed: 28687616     


Immunofluorescent images of HuR (green) in MIA PaCa-2 cells treated with PARPi for 12hr. Nuclei were stained with DAPI. Magnification 40X.

BRCA1; 

PubMed: 21917757     


Effects of ABT-888 and/or bortezomib on BRCA1 and RAD51 foci formation. BRCA1 and RAD1 foci induced by ABT-888 were completely resolved in cells cotreated with bortezomib. Image acquisition was performed with an epifluorescence microscope (BX51; Olympus) and multispectral color camera (Nuance FX; CRi) with a 60× or 100× magnification lens and oil immersion.

28687616 21917757
Growth inhibition assay
Cell viability (TNBC cell lines); 

PubMed: 27880910     


BRCA-proficient TNBC cell lines were treated with veliparib in the absence and presence of dinaciclib, demonstrating reduced IC50 values in the presence of dinaciclib.

Cell viability (melanoma cells); 

PubMed: 29956724     


Dose-dependent inhibitory effect of ABT-888 on melanoma cell proliferation. Human melanoma cell lines were exposed to diluents (control; CTRL) or increasing concentrations of ABT-888 for 72 h and their viability was assessed by MTT assay. Absorbance was detected at 540 nm with a microplate reader and data were expressed as a percentage of the CTRL. Data are the means ± SD of 3 experiments performed in triplicate. Statistical significance was calculated against the CTRL (*P<0.05; **P<0.01).

27880910 29956724
In vivo The oral bioavailability of ABT-888 is 56%-92% in mice, Sprague-Dawley rats, beagle dogs, and cynomolgus monkeys after oral administration. [1] ABT-888 (25 mg/kg i.p.) could improve tumor growth delay in a NCI-H460 xenograft model with well tolerated. Combination with radiation, ABT-888 decreases the tumor vessel formation. [3] ABT-888 reduces intratumor PAR levels by more than 95% at a dose of 3 and 12.5 mg/kg in A375 and Colo829 xenograft models and the suppression could be maintained over time. [4]

Protocol

Animal Research:

[1]

- Collapse
  • Animal Models: NCI-H460, H460, B16F10 and 9L xenografts in C57BL/6 mice
  • Dosages: ~25 mg/kg
  • Administration: Orally administered
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 17 mg/mL (69.58 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
0.5% methylcellulose+0.2% Tween 80
For best results, use promptly after mixing.
5 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 244.29
Formula

C13H16N4O

CAS No. 912444-00-9
Storage powder
in solvent
Synonyms NSC 737664
Smiles CC1(CCCN1)C2=NC3=C(C=CC=C3[NH]2)C(N)=O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03044795 Withdrawn Drug: Veliparib Cancer University Medical Center Groningen|AbbVie|Dutch Cancer Society November 2019 Phase 2
NCT02723864 Recruiting Drug: Veliparib + VX-970 + Cisplatin Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 9 2017 Phase 1
NCT02483104 Completed Drug: veliparib|Drug: carboplatin|Drug: paclitaxel Ovarian Cancer AbbVie July 2015 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products

Tags: buy Veliparib (ABT-888) | Veliparib (ABT-888) supplier | purchase Veliparib (ABT-888) | Veliparib (ABT-888) cost | Veliparib (ABT-888) manufacturer | order Veliparib (ABT-888) | Veliparib (ABT-888) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID